VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
äŒæ¥ã³ãŒãVNRX
äŒç€ŸåVolitionRX Ltd
äžå Žæ¥Feb 06, 2015
æé«çµå¶è²¬ä»»è
ãCEOãButera (Salvatore Thomas)
åŸæ¥å¡æ°85
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 06
æ¬ç€Ÿæåšå°1489 West Warm Springs Road
éœåžHENDERSON
蚌åžååŒæNASDAQ OMX â NASDAQ Basic Amex
åœUnited States of America
éµäŸ¿çªå·89014
é»è©±çªå·17024251561
ãŠã§ããµã€ãhttps://volition.com/
äŒæ¥ã³ãŒãVNRX
äžå Žæ¥Feb 06, 2015
æé«çµå¶è²¬ä»»è
ãCEOãButera (Salvatore Thomas)